Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

3 1 1

What is this study about?

This clinical trial is focused on studying the treatment of advanced ovarian cancer, specifically in patients who have been newly diagnosed with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study involves the use of several medications, including durvalumab, olaparib, and bevacizumab. Durvalumab, also known by its code name MEDI4736, is a type of medication that helps the immune system fight cancer. Olaparib, also referred to as AZD2281, is a medication that targets cancer cells with specific genetic mutations. Bevacizumab is a medication that inhibits the growth of blood vessels that supply nutrients to tumors.

The purpose of this study is to evaluate the effectiveness and safety of these medications when used in combination with standard chemotherapy. The study is designed to compare different treatment approaches: one group will receive standard chemotherapy and bevacizumab, followed by maintenance therapy with bevacizumab alone, while other groups will receive additional treatments with durvalumab or a combination of durvalumab and olaparib. The study is conducted in a randomized and double-blind manner, meaning that participants are randomly assigned to different treatment groups, and neither the participants nor the researchers know which treatment each participant is receiving.

Participants in the study will undergo a series of treatments over a period of time, with regular monitoring to assess the progression of the disease and the response to the treatment. The study aims to determine how well these treatments work in preventing the cancer from getting worse and to evaluate the overall survival of the participants. The trial will also look at other factors such as the duration of response to the treatment and the quality of life of the participants. The study is expected to continue until 2026, with the goal of providing valuable information on the treatment of advanced ovarian cancer.

1 joining the study

Upon joining the study, the patient is randomly assigned to one of the treatment groups. This process is double-blind, meaning neither the patient nor the researchers know which group the patient is in.

2 initial treatment phase

The patient receives standard chemotherapy combined with bevacizumab. Bevacizumab is administered through an intravenous infusion. The frequency and dosage are determined by the study protocol and the patient’s specific needs.

3 maintenance therapy

After completing the initial treatment phase, the patient enters the maintenance therapy phase. This involves continued treatment with bevacizumab and may include additional medications such as durvalumab and olaparib.

Durvalumab is given as an intravenous infusion, while olaparib is taken orally in the form of film-coated tablets. The dosage and frequency are specified by the study protocol.

4 monitoring and follow-up

Throughout the study, the patient’s health and response to treatment are closely monitored. This includes regular medical assessments and tests to evaluate the effectiveness and safety of the treatment.

The study aims to measure progression-free survival, which is the time from the start of the study until the disease progresses or the patient passes away.

5 end of study participation

The patient’s participation in the study concludes either at the end of the study period or if the patient decides to withdraw from the study. The estimated end date for the study is March 17, 2026.

Who Can Join the Study?

  • Female patients with newly diagnosed advanced ovarian cancer, which includes specific types like high grade serous, high grade endometrioid, clear cell ovarian cancer, carcinosarcoma, primary peritoneal cancer, or fallopian-tube cancer.
  • Patients must be at least 18 years old.
  • Patients should be candidates for surgery to remove as much of the tumor as possible, either before starting treatment or after some initial chemotherapy.
  • Patients must provide a sample of their tumor for specific genetic testing called tBRCA testing.
  • There must be evidence showing whether or not there is a BRCA1/2 mutation in the tumor tissue. BRCA1/2 are genes that, when mutated, can affect cancer risk.
  • Patients should have an ECOG performance status of 0-1, which means they are fully active or have some symptoms but can still carry out light work.
  • Patients must have normal functioning of their organs and bone marrow, which is important for overall health and ability to handle treatment.
  • Women who can have children must show they are not pregnant, either by being postmenopausal or having a negative pregnancy test.

Who Cannot Join the Study?

  • Patients who have not been newly diagnosed with advanced ovarian, fallopian, or primary peritoneal cancer.
  • Patients who do not have high-grade epithelial cancer, which is a type of cancer that starts in the cells on the surface of the ovary, fallopian tube, or peritoneum.
  • Patients who are not in FIGO stage III-IV, which means the cancer is not advanced or has not spread beyond the pelvis.
  • Patients who are not female, as the study is only for women.
  • Patients who are not in the specified age range for the study.
  • Patients who are considered part of a vulnerable population, which means they might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

Site Name City Country Status
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy Warsaw Poland

Verified Sites

Other Sites

Site Name City Country Status
Ospedale San Raffaele S.r.l. Milan Italy
Turku University Hospital Turku Finland
Sygehus Lillebaelt Vejle Sygehus Vejle Denmark
Rheinische Friedrich-Wilhelms-Universitaet Bonn Bonn Germany
Istituto Europeo Di Oncologia S.r.l. Milan Italy
Hopital Beaujon Clichy France
Klinikum Esslingen GmbH Esslingen Am Neckar Germany
Central Hospital Of Northern Pest Military Hospital Budapest Hungary
Hochtaunus-Kliniken gGmbH Bad Homburg Germany
L’Hopital Prive Du Confluent Nantes France
Klinikum Worms gGmbH Worms Germany
Azienda Ulss 3 Serenissima Venice Italy
Romed Klinikum Rosenheim Rosenheim Germany
Azorg Aalst Belgium
Usurxwptup Ob Dffxurzh Debrecen Hungary
Iknnjcis Pjdkaghkymsfhfr Cpnkmk Cauhve Marseille France
Rphneq Sdrpxxkpl Holbæk Denmark
Okcguk Ugjlubxubq Hvvmliid Odense Denmark
Umdphfgryiacetbrjdafg Tfqvxsnry Abj Tuebingen Germany
Cghykts Uhuwclcjzvnqcxcchxkj Bffzyf Kmb Berlin Germany
Ueaccpeqasunlhkhksbnz Mbbyzonq Gdzc Mannheim Germany
Hosfrnjl Cmgamef Slc Cyhgfo Madrid Spain
Amuyysm Uldxyrtnus Hilutxgb Aalborg Denmark
Kuczji Uyngkvosguzvgbcebspvm Gder Linz Austria
Khbyqogh Kyxqsi Gvjp Kassel Germany
Mftsfyb Cszxwr &nonxkh Uvkhtjepqb Oc Fhkfvxpe Freiburg Im Breisgau Germany
Kuiljzji dma Ubrnrwnvpxch Motbjpkj Ayy Munich Germany
Uedcnefcqf Om Sjyoif Szeged Hungary
Uklngpeseual Lafozrw Leipzig Germany
Cgaglpw Ofobdaks Cnuham Bvzkra Eabh Burgas Bulgaria
Ccpmcb Lygq Bqkeqa Lyon France
Upsojhsmfk Mfyhhlh Cqwppt Hwtboofvgrdpevhpp Hamburg Germany
Uemfaspmdosengfkpldaw Eeirv Aml Essen Germany
Ilxfgdtk fjrq Kaazbwmig Tcnrfmntswaywvsyyxg upx Iivefsxzukps Uds gaeoa Ulm Germany
Ujvkcsoifhebtwvazixxu Syrlloztniqvwrrueu Aps Kiel Germany
Hmtlfvjq Uezklcqidbpcy 1z Dr Otwiwua Madrid Spain
Uetecimzjv Dkeyp Sqtob Dr Bxuowlk Brescia Italy
Czkroo Hcuoyzkgqqx Urqzfzgttkxfj Dxwjcp Gqgjrkr Syheoufzgfdhmmtdvtjkwtgvso Namur Belgium
Wryhliyrxrj Wlrpvlasfemifdekeaik Cyjhcdu Ossbjhjne I Tfsxjtnqvovmv Ip Mxtroflagvz W Lxbwe Lodz Poland
Srpimjag Plddsbfiq Sek z ogsh Gdynia Poland
Vynug Sint-Niklaas Belgium
Ctqtcho Ocnazgmhizu Cdclzc Ptlbyvy Efla Plovdiv Bulgaria
Kemiidkw Olveciffm Adv Oldenburg In Holstein Germany
Gdsooe Obrentnc Mekgricinzinh Bypwfyf Mmuzesxsr Mmiqvoc Reggio Calabria Italy
Okzgxoae Oxhczcgben Ircpnsg Budapest Hungary
Sjsbcp Vcvquxyvn Kxbieh Mlx Oxjezh Kedqet Kaposvar Hungary
Keyztuyf Guzfsvockm gucek Guetersloh Germany
Ssbunjrwnes Ecp Dsnzbeie Heviirla Fro Asibai Tndtjztsrnspmhs Egid Varna Bulgaria
Pknhwjrdrjjejrkmre hpbkciwutfmnefp Oulu Finland
Vpaka Copbxtslgif Kynmtznn Katxsxxyl Karlsruhe Germany
Mntibbd Ctbqym Napbsbfx Csyhgsib Ezoi Sofia Bulgaria
Uonueazhbufqp Swdjzml Kbmvvrdbn Ne 2 Pdz W Snkvkqofac Szczecin Poland
Tnsibrlgdqxjirlvruy Gwjqdsoj Atefwmem Gngj Saalfeld Germany
Cpvptj Hqyujpsbvzf Eh Utkjnobbliuqf Dl Lsxbcfw Limoges France
Bqpakild Uusdvnkefj Huypbgmu Cmmeta Besançon France
Klhrdgli Sxcjnrtsh Rumyque Rostock Germany
Seu Ewypwjgrk Kydjduiezkj Gkck Cologne Germany
Akhsdh Unjqucjwtf Hopkyyyg Aarhus Denmark
Axnirbehra Mkzqxjm Hcdymqyy Lecco Italy
Kuruxdjietxsgw Dtacriai Duesseldorf Germany
Gbhvrlgrsabnkeghq Vktrztbiv Pupk Apvmor Eeduxmqy Oonblj Kakliv Gyor Hungary
Zgof Mqrowz Suawf Rvnbzc Kuqsos Zalaegerszeg Hungary
Nmnsfbhu Iwklhvad Omvnmhoax Idp Mczte Smqdqinztbaypwcsicugxtzccgjn Iqtkoktc Bwyehijo Cracow Poland
Geyqau Udpmclcdsx Fcmurdgkx Frankfurt Germany
Fhlmxfcg Alddgvkdjqii Dv Mnajl Do Tejvcrmz Fxt Terrassa Spain
Gdpbjt Hsbsgxapqhj Dqajsuknwas Czofp Svgje Sdjzh Paris France
Pfegqwgjunsgj hqwfchdknolmaug Kuopio Finland
Hewbdxiq Azfxdr Cytdgarqg Vigo Spain
Sfruvqpksgqu Kyfpjsyq Ktbkjldcc gldnj Karlsruhe Germany
Lclaxojyotckgwfpejyatx dzt Selzb Sxewhopjbae Gwdy Schweinfurt Germany
Sney Khhbblxf Oasflhlbl Gtke Offenbach Am Main Germany
Rubdepzrcipx Chwppu Coay Skcojw Floresti Romania
Icywvkwn Mlhyojkbgm Mlycazpghp Paris France
Rff Kqxbzvh Lnmfqhodkaqybosrcirxey gkwps Ludwigsburg Germany
Aiiumzd Oczlgtouwsm Oxlkdm Mbfkecbdzo Dm Tlkyih Turin Italy
Ml Anfqozyh Cpyibv Cksiza Madrid Spain
Kskmboza Bvordzham gwbig Bielefeld Germany
Kbsbuvta Ebsaxwznxjfzsrchskawdnhf Hwaxrvoitisplfgpi Essen Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Not recruiting
30.01.2019
Belgium Belgium
Not recruiting
30.01.2019
Bulgaria Bulgaria
Not recruiting
30.01.2019
Denmark Denmark
Not recruiting
30.01.2019
Finland Finland
Not recruiting
30.01.2019
France France
Not recruiting
30.01.2019
Germany Germany
Not recruiting
30.01.2019
Hungary Hungary
Not recruiting
30.01.2019
Italy Italy
Not recruiting
30.01.2019
Poland Poland
Not recruiting
30.01.2019
Romania Romania
Not recruiting
30.01.2019
Spain Spain
Not recruiting
30.01.2019

Trial locations

Durvalumab is a medication used in this trial to help the immune system attack cancer cells. It is a type of immunotherapy that works by blocking a protein that stops the immune system from working properly, allowing it to better fight the cancer.

Bevacizumab is a medication that helps to prevent the growth of new blood vessels that tumors need to grow. By blocking these blood vessels, it can help to slow down or stop the growth of the cancer.

Olaparib is a medication that targets cancer cells with specific genetic defects. It works by interfering with the cancer cells’ ability to repair their DNA, which can lead to the death of these cells. This medication is used as part of the maintenance therapy in the trial to help keep the cancer from coming back after initial treatment.

Investigated Diseases:

High Grade Epithelial Ovarian Cancer – This is a type of cancer that begins in the cells on the surface of the ovary. It is characterized by its rapid growth and tendency to spread to other parts of the body, often being diagnosed at an advanced stage. The disease progresses as cancer cells multiply and invade nearby tissues, potentially spreading to the abdominal lining and other organs. Symptoms may include abdominal bloating, pelvic pain, and changes in bowel habits. The progression of the disease can lead to the accumulation of fluid in the abdomen and other complications. Early detection is challenging due to the subtlety of initial symptoms.

Fallopian Tube Cancer – This rare cancer originates in the fallopian tubes, which connect the ovaries to the uterus. It often presents with symptoms similar to ovarian cancer, such as pelvic pain and abnormal vaginal discharge. The disease progresses as cancer cells grow and may spread to nearby organs and tissues. It is typically diagnosed at an advanced stage due to the lack of specific early symptoms. The cancer can cause blockages in the fallopian tubes, leading to further complications. As it advances, it may spread to the abdominal cavity and beyond.

Primary Peritoneal Cancer – This cancer develops in the peritoneum, the lining of the abdominal cavity, and is closely related to ovarian cancer. It progresses similarly to ovarian cancer, with cancer cells spreading across the peritoneal surface. Symptoms can include abdominal pain, bloating, and digestive disturbances. The disease often advances before being detected, as early symptoms are non-specific. It can lead to the accumulation of fluid in the abdomen, known as ascites. The cancer may spread to other abdominal organs and tissues as it progresses.

Trial ID:
2022-502747-35-00
Protocol code:
DUO-O/D081RC00001
NCT ID:
NCT03737643
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Open‑Label Extension Study of Avutometinib Alone or with Defactinib in Patients with Recurrent Low‑Grade Serous Ovarian Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    France
  • Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    France Ireland Italy Romania Spain